



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/561,829
		Filing Date	December 21, 2005
		First Named Inventor	Shaharyar Khan
		Group Art Unit	1636
		Examiner Name	Kimberly A. Makar
		Attorney Docket Number	GNC 0001
Sheet	1	of	2

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	7 ²
		BAYONA-BAFALUY, "Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease," <i>Proc. Natl. Acad. Sci. U S A.</i> 102(40):14392-7(2005).	
		D'SOUZA "Gene therapy of the other genome: the challenges of treating mitochondrial DNA defects" <i>Pharm Res.</i> 24(2):228-38(2007).	
		DEL GAIZO, "A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta," <i>Mol. Ther.</i> 7(6):720-30(2003).	
		FLIERL, "Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid," <i>Mol. Ther.</i> 7(4):550-7(2003).	
		KHAN, "Development of mitochondrial gene replacement therapy," <i>J. Bioenergetics and Biomembranes</i> 36L387-393(2004).	
		MALIGA, "Plant Biotechnology 2007: all three genomes make contributions to progress" <i>Current Opinion in Biotech.</i> 18:97-99(2007).	
		MURPHY, "Selective Targeting of Bioactive Compounds to Mitochondria," <i>Trends in Biotech.</i> 15(8):326-30(1997).	
		SEIBEL, "Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases," <i>Nucleic Acids Res.</i> 23(1):10-17(1995).	
		SHORE, "Import and insertion of proteins into the mitochondrial outer membrane" <i>Eur. J. Biochem.</i> 227:9-18(1995)	
		SLOOTS, "Recombinant derivatives of the human high-mobility group protein HMGB2 mediate efficient nonviral gene delivery" <i>FEBS</i> 272:4221-4236(2005).	
		SRIVASTAVA, "Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease," <i>Hum. Mol. Genet.</i> 10(26):3093-9(2001).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		10/561,829	
				Filing Date		December 21, 2005	
				First Named Inventor		Shaharyar Khan	
				Group Art Unit		1636	
				Examiner Name		Kimberly A. Makar	
Sheet	2	of	2	Attorney Docket Number		GNC 0001	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		TANAKA, "Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria," <i>J. Biomed. Sci.</i> 9(6 Pt 1):534-41(2002).	
		VESTWEBER, "DNA-protein conjugates can enter mitochondria via the protein import pathway," <i>Nature</i> 338(6211):170-2(1989).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

